Camptothecin-Loaded Liposomes with α-Melanocyte-Stimulating Hormone Enhance Cytotoxicity Toward and Cellular Uptake by Melanomas: An Application of Nanomedicine on Natural Product

10.4103/2225-4110.110423

Chih-Hung Lin；Saleh A. Al-Suwayeh；Chih-Feng Hung；Chih-Chieh Chen；Jia-You Fang

Camptothecin ； Controlled release ； Liposomes ； α-melanocyte-stimulating hormone ； Melanoma

Journal of Traditional and Complementary Medicine

3卷2期（2013 / 04 / 01）

102 - 109

英文

In this study, we attempted to develop functional liposomes loaded with camptothecin and attached to α-melanocyte-stimulating hormone (α-MSH) to target melanoma cells. The liposomes were mainly composed of phosphatidylcholine, cholesterol, and stearylamine, and were characterized by the vesicle size, zeta potential, camptothecin encapsulation efficiency, and release behavior. Results revealed that α-MSH liposomes possessed an average size of approximately 250 nm with a surface charge of 60 mV. Camptothecin was successfully entrapped by the targeted liposomes with an encapsulation percentage of nearly 95%. The liposomes provided sustained and controlled camptothecin release. Non-targeted liposomes with the drug exerted superior cytotoxicity against melanomas compared to the free control. Cell viability was reduced from 48% to 32% compared to conventional liposomes. Peptide ligand conjugation further promoted cytotoxicity to 18% viability, which was a 2.7-fold decrease versus the free control. According to the images of fluorescence microscopy, α-MSH liposomes exhibited greater cell endocytosis than did non-targeted liposomes and the free control. α-MSH liposomes were predominantly internalized in the cytoplasm. These findings demonstrate that α-MSH liposomes could enhance the anti-melanoma activity of camptothecin owing to their targeting ability and controlled drug delivery.

1. Barbugli, PA,Siqueira‑Moura, MP,Espreafico, EM,Tedesco, AC(2010).In vitro phototoxicity of liposomes and nanocapsules containing chloroaluminum phthalocyanine on human melanoma cell line.J Nanosci Nanotechnol,10,569-573.
2. Carrigan, SW,Fox, PC,Wall, ME,Wani, MC,Bowen, JP(1997).Comparative molecular field analysis and molecular modeling studies of 20‑(s)‑camptothecin analogs as inhibitors of DNA topoisomerase I and anticancer/antitumor agents.J Comput‑Aided Mol Des,11,71-78.
3. Elbayoumi, TA,Torchilin, VP(2009).Tumor‑targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin‑loaded, long‑circulating liposomes modified with cancer‑specific monoclonal antibody.Clin Cancer Res,15,1973-1980.
4. Fang, JY,Hung, CF,Hua, SC,Hwang, TL(2009).Acoustically active perfluorocarbon nanoemulsions as drug delivery carriers for camptothecin: Drug release and cytotoxicity against cancer cells.Ultrasonics,49,39-46.
5. Fang, JY,Hung, CF,Hwang, TL,Huang, YL(2005).Physicochemical characteristics and in vivo deposition of liposome‑encapsulated tea catechins by topical and intratumor administrations.J Drug Target,13,19-27.
6. Fenske, DB,Cullis, PR(2008).Liposomal nanomedicines.Exp Opin Drug Deliv,5,25-44.
7. Ferrin, G,Linares, CI,Muntane, J(2011).Mitochondrial drug targets in cell death and cancer.Curr Pharm Des,17,2002-2016.
8. Glover, DJ,Ng, SM,Mechler, A,Martin, LL,Jans, DA(2009).Multifunctional protein nanocarriers for targeted nuclear gene delivery in nondividing cells.FASEB J,23,2996-3006.
9. Gupta, Y,Ganesh, N,Kohli, DV,Jain, SK(2011).Development and characterization of doxorubicin bearing vitamin B12 coupled sterically stabilized liposomes for tumor targeting.Curr Nanosci,7,427-435.
10. Hidalgo, E,Dominguez, C(1998).Study of cytotoxicity mechanisms of silver nitrate in human dermal fibroblasts.Toxicol Lett,98,169-179.
11. Hsu, SH,Al‑Suwayeh, SA,Chen, CC,Chi, CH,Fang, JY(2011).PEGylated liposomes incorporated with nonionic surfactants as an apomorphine delivery system targeting the brain: In vitro release and in vivo real‑time imaging.Curr Nanosci,7,191-199.
12. Hsu, SH,Wen, CJ,Al‑Suwayeh, SA,Chang, HW,Yen, TC,Fang, JY(2010).Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers(NLCs) for targeting the brain: Apomorphine as a model drug.Nanotechnology,21,405101.
13. Huang, YB,Tsai, MJ,Wu, PC,Tsai, YH,Wu, YH,Fang, JY(2011).Elastic liposomes as carriers for oral delivery and the brain distribution of (+)‑catechin.J Drug Target,19,709-718.
14. Huang, ZR,Hua, SC,Yang, YL,Fang, JY(2008).Development and evaluation of lipid nanoparticles for camptothecin delivery: A comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion.Acta Pharmacol Sin,29,1094-1102.
15. Hwang, TL,Lee, WR,Hua, SC,Fang, JY(2007).Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas.J Dermatol Sci,46,11-20.
16. Ito, A,Fujioka, M,Yoshida, T,Wakamatsu, K,Ito, S,Yamashita, T(2007).4‑S‑Cysteaminylphenol‑loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma.Cancer Sci,98,424-430.
17. Kaur, IP,Bhandari, R,Bhandari, S,Kakkar, V(2008).Potential of solid lipid nanoparticles in brain targeting.J Control Release,127,97-109.
18. Li, H,Song, JH,Park, JS,Han, K(2003).Polyethylene glycol‑coated liposomes for oral delivery of recombinant human epidermal growth factor.Int J Pharm,258,11-19.
19. Lu, W,Xiong, C,Zhang, G,Huang, Q,Zhang, R,Zhang, JZ(2009).Targeted photothermal ablation of murine melanomas with melanocyte‑stimulating hormone analog‑conjugated hollow gold nanospheres.Clin Cancer Res,15,876-885.
20. Marcato, PD,Durán, N.(2008).New aspects of nanopharmaceutical delivery systems.J Nanosci Nanotechnol,8,2216-2229.
21. Miao, Y,Quinn, TP(2008).Peptide‑targeted radionuclide therapy for melanoma.Crit Rev Oncol/Hematol,67,213-228.
22. Niu, R,Zhao, P,Wang, H,Yu, M,Cao, S,Zhang, F(2011).Preparation, characterization, and antitumor activity of paclitaxel‑loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes.J Drug Target,19,373-381.
23. Ogawa, Y,Kawahara, H,Yagi, N,Kodaka, M,Tomohiro, T,Okada, T(1999).Synthesis of a novel lipopeptide withα‑melanocyte‑stimulating hormone peptide ligand and its effect on liposome stability.Lipids,34,387-394.
24. Peer, D,Karp, JM,Hong, S,Farokhzad, OC,Margalit, R,Langer, R(2007).Nanocarriers as an emerging platform for cancer therapy.Nat Nanotechnol,2,751-760.
25. Raposinho, PD,Correia, JD,Oliveira, MC,Santos, I(2010).Melanocortin‑1 receptor‑targeting with radiolabeled cyclic α‑melanocyte‑stimulating hormone analogs for melanoma imaging.Biopolymers,94,820-829.
26. Rudolf, E,Rudolf, K,Cervinka, M(2011).Camptothecin induces p53‑dependent and ‑independent apoptogenic signaling in melanoma cells.Apoptosis,16,1165-1176.
27. Santel, A,Aleku, M,Keil, O,Endruschat, J,Esche, V,Burieux, B(2006).RNA interference in the mouse vascular endothelium by systemic administration of siRNA‑lipoplexes for cancer therapy.Gene Ther,13,1360-1370.
28. Schiöth, HB,Mutulis, F,Muceniece, R,Prusis, P,Wikberg, JE(1998).Selective properties of C‑ and N‑terminals and core residues of the melanocyte‑stimulating hormone on binding to the human melanocortin receptor subtypes.Eur J Pharmacol,349,359-366.
29. Schiöth, HB,Mutulis, F,Muceniece, R,Prusis, P,Wikberg, JES(1998).Discovery of novel melanocortin4 receptor selective MSH analogues.Br J Pharmacol,124,75-82.
30. Thomas, CJ,Rahier, NJ,Hecht, SM(2004).Camptothecin: Current perspectives.Bioorg Med Chem,12,1585-1604.
31. Thompson, JF,Scolyer, RA,Kefford, RF(2005).Cutaneous melanoma.Lancet,365,687-701.
32. Tippayamontri, T,Kotb, R,Paquette, B,Sanche, L(2011).Cellular uptake and cytoplasm/DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116.Invest New Drugs,29,1321-1327.
33. Tran, MA,Watts, RJ,Robertson, GP(2009).Use of liposomes as drug delivery vesicles for treatment of melanoma.Pigment Cell Melanoma Res,22,388-399.
34. Wang, H,Zhao, P,Liang, X,Gong, X,Song, T,Niu, R(2010).Folate‑PEG coated cationic modified chitosan‑cholesterol liposomes for tumor‑targeted drug delivery.Biomaterials,31,4129-4138.
35. Watanabe, M,Kawano, K,Toma, K,Hattori, Y,Maitani, Y(2008).In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin.J Control Release,127,231-238.
36. Xu, L,Wempe, MF,Anchordoquy, TJ(2011).The effect of cholesterol domains on PEGylated liposomal gene delivery in vitro.Ther Deliv,2,451-460.
37. Yagi, N,Ogawa, Y,Kodaka, M,Okada, T,Tomohiro, T,Konakahara, T(2000).Preparation of functional liposomes with peptide ligands and their binding to cell membranes.Lipids,35,673-679.
38. Zhao, P,Wang, H,Yu, M,Cao, S,Zhang, F,Chang, J(2010).Paclitaxel‑loaded, folic‑acid‑targeted and TAT‑peptide‑conjugated polymeric liposomes: In vitro and in vivo evaluation.Pharm Res,27,1914-1926.